Literature DB >> 23010135

Continuous buccolingual masticatory dyskinesia in Parkinson's disease.

Claire Meyniel1, Pascal Derkinderen, Bernard Giumelli, Philippe Damier.   

Abstract

Usually, levodopa-induced dyskinesia does not remain unchanged throughout the day in Parkinson's disease (PD) patients and varies according to the level of correction of PD symptomatology provided by the treatment. We observed two PD patients with unusual buccolingual masticatory movements which did not seem to fluctuate, either throughout the day during dopaminergic treatment or during a standardised levodopa challenge. After their dopaminergic treatment had been changed to a less pulsatile form of administration (ie, the use of dopamine agonist alone in the first patient and an increase in the dosage of dopamine agonist with a low dose of levodopa in the second), these abnormal movements totally disappeared in the first patient and were greatly improved in the second. These observations suggest that levodopa can have prolonged effects (several days) and induce prolonged buccolingual masticatory movements similar in type to those classically observed with dopamine receptor antagonists (neuroleptics).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010135      PMCID: PMC5685285          DOI: 10.1136/bcr.09.2008.0910

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Foot, hand, face and eye representation in the human striatum.

Authors:  Emmanuel Gerardin; Stéphane Lehéricy; Jean-Baptiste Pochon; Sophie Tézenas du Montcel; Jean-François Mangin; Fabrice Poupon; Yves Agid; Denis Le Bihan; Claude Marsault
Journal:  Cereb Cortex       Date:  2003-02       Impact factor: 5.357

Review 2.  Tardive syndromes in the elderly.

Authors:  Kelvin L Chou; Joseph H Friedman
Journal:  Clin Geriatr Med       Date:  2006-11       Impact factor: 3.076

3.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Early morning off-medication dyskinesias, dystonia, and choreic subtypes.

Authors:  E Cubo; J M Gracies; R Benabou; C W Olanow; R Raman; S Leurgans; C G Goetz
Journal:  Arch Neurol       Date:  2001-09

5.  Atypical and typical cranial dystonia following dental procedures.

Authors:  A Schrag; K P Bhatia; N P Quinn; C D Marsden
Journal:  Mov Disord       Date:  1999-05       Impact factor: 10.338

Review 6.  Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.

Authors:  Joseph Jankovic
Journal:  Mov Disord       Date:  2005       Impact factor: 10.338

Review 7.  The spectrum of levodopa-induced dyskinesias.

Authors:  S Fahn
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

8.  Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease.

Authors:  S Zaja-Milatovic; D Milatovic; A M Schantz; J Zhang; K S Montine; A Samii; A Y Deutch; T J Montine
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

9.  Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.

Authors:  Christine Konradi; Jenny E Westin; Manolo Carta; Molly E Eaton; Katarzyna Kuter; Andrzej Dekundy; Martin Lundblad; M Angela Cenci
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

10.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.